151 related articles for article (PubMed ID: 3050300)
1. Treatment of Parkinson's disease with pergolide: a double-blind study.
Ahlskog JE; Muenter MD
Mayo Clin Proc; 1988 Oct; 63(10):969-78. PubMed ID: 3050300
[TBL] [Abstract][Full Text] [Related]
2. Pergolide: long-term use in Parkinson's disease.
Ahlskog JE; Muenter MD
Mayo Clin Proc; 1988 Oct; 63(10):979-87. PubMed ID: 3050301
[TBL] [Abstract][Full Text] [Related]
3. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.
Olanow CW; Fahn S; Muenter M; Klawans H; Hurtig H; Stern M; Shoulson I; Kurlan R; Grimes JD; Jankovic J
Mov Disord; 1994 Jan; 9(1):40-7. PubMed ID: 8139604
[TBL] [Abstract][Full Text] [Related]
4. Pergolide : A Review of its Pharmacology and Therapeutic Use in Parkinson's Disease.
Markham A; Benfield P
CNS Drugs; 1997 Apr; 7(4):328-40. PubMed ID: 27520755
[TBL] [Abstract][Full Text] [Related]
5. Analysis of mortality in pergolide-treated patients with Parkinson's disease.
Sayler ME; Street JS; Bosomworth JC; Potvin JH; Kotsanos JG
Neuroepidemiology; 1996; 15(1):26-32. PubMed ID: 8719046
[TBL] [Abstract][Full Text] [Related]
6. Randomized trial of tolcapone versus pergolide as add-on to levodopa therapy in Parkinson's disease patients with motor fluctuations.
Koller W; Lees A; Doder M; Hely M;
Mov Disord; 2001 Sep; 16(5):858-66. PubMed ID: 11746615
[TBL] [Abstract][Full Text] [Related]
7. Switching from pergolide to pramipexole in patients with Parkinson's disease.
Hanna PA; Ratkos L; Ondo WG; Jankovic J
J Neural Transm (Vienna); 2001; 108(1):63-70. PubMed ID: 11261747
[TBL] [Abstract][Full Text] [Related]
8. Double-blind controlled study of pergolide mesylate as an adjunct to Sinemet in the treatment of Parkinson's disease.
Olanow CW; Alberts MJ
Adv Neurol; 1987; 45():555-60. PubMed ID: 3548266
[No Abstract] [Full Text] [Related]
9. High doses of pergolide improve clinical global impression in advanced Parkinson's disease:- a preliminary open label study.
Arnold G; Gasser T; Storch A; Lipp A; Kupsch A; Hundemer HP; Schwarz J
Arch Gerontol Geriatr; 2005; 41(3):239-53. PubMed ID: 16029905
[TBL] [Abstract][Full Text] [Related]
10. High-dose treatment with pergolide in Parkinson's disease patients with motor fluctuations and dyskinesias.
Storch A; Trenkwalder C; Oehlwein C; Winkelmann J; Polzer U; Hundemer HP; Schwarz J
Parkinsonism Relat Disord; 2005 Sep; 11(6):393-8. PubMed ID: 15993640
[TBL] [Abstract][Full Text] [Related]
11. Parallel double-blind study of pergolide in Parkinson's disease.
Jankovic J; Orman J
Adv Neurol; 1987; 45():551-4. PubMed ID: 3548265
[No Abstract] [Full Text] [Related]
12. Double-blind trial of pergolide for Parkinson's disease.
Diamond SG; Markham CH; Treciokas LJ
Neurology; 1985 Mar; 35(3):291-5. PubMed ID: 3883232
[TBL] [Abstract][Full Text] [Related]
13. Improvement of motor fluctuations in patients with Parkinson's disease following treatment with high doses of pergolide and cessation of levodopa.
Schwarz J; Scheidtmann K; Trenkwalder C
Eur Neurol; 1997; 37(4):236-8. PubMed ID: 9208264
[TBL] [Abstract][Full Text] [Related]
14. Pergolide for levodopa-induced complications in Parkinson's disease.
Clarke C E; Speller J M
Cochrane Database Syst Rev; 2000; (2):CD000235. PubMed ID: 10796704
[TBL] [Abstract][Full Text] [Related]
15. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
[TBL] [Abstract][Full Text] [Related]
16. Pergolide. A review of its pharmacological properties and therapeutic potential in Parkinson's disease.
Langtry HD; Clissold SP
Drugs; 1990 Mar; 39(3):491-506. PubMed ID: 2184010
[TBL] [Abstract][Full Text] [Related]
17. Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses.
Okereke CS; Kirby L; Kumar D; Cullen EI; Pratt RD; Hahne WA
Br J Clin Pharmacol; 2004 Nov; 58 Suppl 1(Suppl 1):41-9. PubMed ID: 15496222
[TBL] [Abstract][Full Text] [Related]
18. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial.
Hauser RA; Hsu A; Kell S; Espay AJ; Sethi K; Stacy M; Ondo W; O'Connell M; Gupta S;
Lancet Neurol; 2013 Apr; 12(4):346-56. PubMed ID: 23485610
[TBL] [Abstract][Full Text] [Related]
19. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson's disease.
Pahwa R; Lyons KE; Hauser RA; Fahn S; Jankovic J; Pourcher E; Hsu A; O'Connell M; Kell S; Gupta S;
Parkinsonism Relat Disord; 2014 Feb; 20(2):142-8. PubMed ID: 24055014
[TBL] [Abstract][Full Text] [Related]
20. Further studies with pergolide in Parkinson disease.
Lieberman AN; Goldstein M; Gopinathan G; Leibowitz M; Neophytides A; Walker R; Hiesiger E; Nelson J
Neurology; 1982 Oct; 32(10):1181-4. PubMed ID: 6889703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]